INTS — Intensity Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $8.75m
- $6.16m
Annual income statement for Intensity Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | C2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 6.22 | 8.01 | 7.55 | 10.6 | 16.6 |
| Operating Profit | -6.22 | -8.01 | -7.55 | -10.6 | -16.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -6.03 | -7.9 | -7.58 | -10.5 | -16.3 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -6.03 | -7.9 | -7.58 | -10.5 | -16.3 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.03 | -7.9 | -7.58 | -10.5 | -16.3 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.03 | -7.9 | -7.58 | -11.9 | -16.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.46 | -0.603 | -0.579 | -0.7 | -1.17 |